POSA49 Projecting the Long-Term Benefits of Venetoclax Combination Therapies for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy: An Assessment of Net Health Benefit
Abstract
Authors
AC Schuh K Pratz J Lachaine HS Suh X Li X Chai J Xie C Gu CN Bui